RxDoctor Payments Data

David Huang

Infectious Disease · Houston, TXNPI 1215943865

Payments from drug & device makers

What this record shows

Madrigal Pharmaceuticals accounts for 91.0% of it on its own, with 3 other manufacturers making up the rest.

$1,514in general payments, 2019–2025

Across 16 payments — averaging $94.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$1K
  • Ipsen Biopharmaceuticals, Inc$73
  • Orphalan Inc$32
  • Gilead$30
$882,118in research payments, 2019–2025

Across 189 payments — averaging $4667.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Madrigal Pharmaceuticals$522K
  • Boehringer Ingelheim International GmbH$291K
  • Astrazeneca UK Limited$35K
  • Boehringer Ingelheim$30K
  • Eli Lilly$4K

What the payments were for

  • Travel & lodging$83755%
  • Food & beverage$67745%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Madrigal Pharmaceuticals11$1,379
Ipsen Biopharmaceuticals, Inc3$73
Orphalan Inc1$32
Gilead1$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,514 in reported general payments places this provider in the 65th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas →

Other infectious disease in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →